Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-a as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Loading...
Identifiers
Publication date
2009
Start date of the public exhibition period
End date of the public exhibition period
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Annals of Oncology
Share
Abstract
Background: The purpose of this study is to evaluate the impact on the health-related quality of life (HRQoL) of
sunitinib versus interferon-alpha (IFN-a) treatment in patients with metastatic renal cell carcinoma (mRCC).
Patients and methods: In all, 304 mRCC patients (European cohort) were randomized 1 : 1 to receive sunitinib (50
mg/day for 4 weeks, followed by 2 weeks off) or IFN-a (9 million units s.c. injection three times/week). The following
questionnaires were completed (days 1 and 28 per cycle): Functional Assessment of Cancer Therapy-General (FACTG), the FACT-Kidney Symptom Index and the EuroQol Group’s EQ-5D self-report questionnaire (EQ-5D). Results
correspond to an ongoing trial with progression-free survival time as primary end point, and patients were still being
followed up. Data were analyzed using repeated measures mixed effects models (MEMs) that allow the inclusion of
initial differences and uncompleted repeated measures, with the assumption of data missing at random. Six-cycle
results were included.
Results: Results consistently showed that patients in sunitinib group experienced statistically significantly milder
kidney-related symptoms, better cancer-specific HRQoL and general health status (in social utility scores) during the
study period as measured by these patient-reported outcome end points. No statistical differences between groups
were found on the FACT-G physical well-being subscale or the EQ-5D VAS values.
Conclusions: Results from MEM showed the sunitinib’s benefit on HRQoL compared with IFN-a.
Doctoral program
Description
Keywords
Health-related quality of life, Interferon-a, Patient-reported outcomes, Sunitinib